New Opportunity: Kasten Inc. (OTCMKTS: KAST)
Last week’s action pushed our 2017 performance up yet another big notch, with a 53% rip in our late week alert. The rich get richer. That’s been the story.
And, while it won’t always feel quite this easy, momentum does tend to stretch out, because we are trading in a very favorable market. Strong picks are grabbing a tailwind as more and more money floods into small and micro-cap equities.
Our newest alert may well further attest to that fact: KAST is a biopharmaceutical stock showing a tremendous amount of technical momentum, setting some ambitious 2017 goals, and working with perhaps the smallest float we’ve ever come across.
Don’t hesitate on this one or it may be out of sight in a blink.
Company: Kasten Inc.
Latest News: http://finance.yahoo.com/q/h?s=KAST+Headlines
Company Website: http://www.kastenbiopharma.com
Who is KAST
Kasten Inc. (OTCMKTS: KAST) is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceuticals and devices designed to prevent and treat serious conditions arising in the hospital and adjacent clinical settings.
According to their materials, the company is principally focused on delivering solutions to those wards in which the care pathway is burdened by high morbidity, mortality, and cost.
As the company notes, “Our initial goal is to market the first-in-class in situ product for the prevention of surgical site infections in abdominal surgeries.”
In a recent corporate update, Jose Delgado, CEO of Kasten, Inc., stated, “We are pleased with our go forward strategies to build shareholder value in an industry that continues to show growth. Biotech drugs have steadily carved a niche for themselves in the pharma market, and our plan is to capitalize on specialty drugs and personalized medicine.”
According to the company’s most recent release, On January 3, 2017, the Company announced a Joint Venture (JV) Agreement with Dakota Life Sciences. The Company is in the process of setting up the JV in the state of Nevada. Per the agreement, the name of the JV shall be KD Joint Venture, Inc. and the purpose shall be to develop, fund, and market Site Specific Penetration Technology (SSPT) biopharmaceutical products.
DAKOTA Life Sciences has completed formulation development, validation, safety, and efficacy testing on more than a dozen Over-The-Counter life sciences products. Revenues from these proprietary products will commence soon, and will be ongoing while the Company refines its prescription product regulatory approval trials designs for several RX products. The combination of imminent OTC revenue and near term Rx product revenue from high efficacy pharmaceuticals creates several assets from which to drive investor value.
The Rx products are expected to receive FDA Fast Track designations, as they are focused on improved delivery of known drugs – resulting in powerful efficacy improvements. This is expected to dramatically reduce the risk, timing, and cost of these FDA approval pathways. Qualified Infectious Disease Product designations will also be sought for several of the Rx product approvals. This designation, once achieved, will enable additional exclusivity for the designated products.
On December 2, 2016, the Company announced a letter of intent with Gulf Coast Pharmaceuticals to acquire formulas for Alzheimer’s disease and Erectile Dysfunction. As a result of its due diligence review, the Company has decided not to pursue this opportunity.
According to OTC Markets, as of July 2016, the float for KAST was listed at just 270K, which is one of the smallest we’ve ever come across.
The stock has been in a very strong momentum trend that has taken it above an upward-sloped set of major moving averages, as should be clear in the chart below. The stock is now testing trend support at the 50-day simple moving average.
With such a small float and an upward bias to recent action, the fact that average daily volume is consistently growing should not be overlooked.
KAST (Kasten Inc.) is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceuticals and devices designed to prevent and treat serious conditions arising in the hospital and adjacent clinical settings. The company is principally focused on delivering solutions to those wards in which the care pathway is burdened by high morbidity, mortality, and cost.
“Our initial goal is to market the first-in-class in situ product for the prevention of surgical site infections in abdominal surgeries.”
- KAST just announced a Joint Venture Agreement with Dakota Life Sciences to develop, fund, and market Site Specific Penetration Technology (SSPT) biopharmaceutical products.
- KAST has a small trading float of just 270K, which suggests the stock could launch higher on any additional influx of interest.
- KAST is pushing higher in a bullish trend channel on gradually rising volume.
- KAST recently recorded a MACD Bullish upward explosion to kick off a solid momentum trend to the upside.
In KAST, we are dealing with a tiny float play in the biotech space. The company has a new deal in formation with a top-tier player to fund and attack areas in the biopharma space that offer the best ROI upon approach. This is every bit the nimble opportunist. That’s a plus for investors.
In addition, the stock is acting extremely well, with bullish trending action in place and the stock cruising above the major MA’s on rising volume. That’s certainly just what you want to see. However, the action has broken just a bit, with the stock taking a little dip to the South, which offers us a tactical opportunity back to the North.
With this tiny float, you don’t want to nod off for a second, because you might glance up and see the stock out of range.
The disclaimer is to be read and fully understood before using our site Stockonhighalert.com also referred to as SOHA . This report/release/video profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. Never invest in any stock discussed on Stockonhighalert.com or SOHA’s newsletter unless you can afford to lose your entire investment. Never listen to anyone on SOHA message boards or private messages sent by any user or member who offers any sort of financial advice. Please consult with a certified financial advisor before making any investment decisions. SOHA and any affiliates and information providers make no implied or expressed warranties on the information provided. Please verify quotes with your investment manager before making investment decisions. This is not to be construed as a solicitation to buy or sell securities. Any stock or featured companies on SOHA web site and/or newsletter involves a high degree of risk and volatility, and all investors should know that they may lose a portion or all of their investment if they decide to purchase any stock mentioned or talked about on SOHA or message boards. SOHA makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or members and does not guarantee the correctness, completeness or quality of information and statements presented on SOHA . Any such information or statements should be deemed apocryphal and opinions only. Neither SOHA , nor any of its affiliates, are registered investment advisors or broker dealers and do not make recommendations to buying, holding, or selling of any securities. MBSP simply provides a starting point for site members and viewers to compare their own thoughts against those here on the message boards at SOHA. The onus is on site members and viewers to complete their own due diligence. SOHA members and viewers should always make their own financial decisions. The accuracy and completeness of the information within any report, newsletter or on website message boards is only as reliable as the information that is provided by SOHA members and users. SOHA does not verify the information, and makes no warranty that the information is accurate. SOHA members, readers and viewers are cautioned that small and micro-cap stocks are high-risk investments and that all investment dollars can be lost. We suggest you consult a professional investment advisor before purchasing any stock. All opinions and postings expressed on SOHA web site are the opinions of SOHA members and users . All information concerning any company is provided by the members and users that create the information box on each board. SOHA recommends you use the information found here on the site and boards as an initial starting point for conducting you own research and conduct your own due diligence (also known as “DD” on any company you read about here at SOHA , in order to determine your own personal opinion of the company before investing in these or any other companies. SOHA assumes all information to be truthful and reliable. However, we cannot and do not warrant or guarantee the accuracy of this information. SOHA is NOT an Investment Advisor, Financial Planning Service or a Stock Brokerage Firm and in accordance with such SOHA is not offering investment advice or promoting any investment strategies. SOHA is not offering securities for sale or solicitation of any offer to buy or sell securities. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. On occasion, SOHA may receive compensation from a third party in relation to the companies being profiled in its Newsletters sent to our members. In such a case SOHA directly mentions such compensations at the bottom of this disclaimer along with the exact form and amount of compensation. in relation to the companies being profiled in its Newsletters sent to our members. In such a case SOHA directly mentions such compensations at the bottom of this disclaimer along with the exact form and amount of compensation.We have been compensated total of 500.00 dollars by Uptrend Media Marketing Group LLC to perform a two day online dissemination and social media marketing for on KAST. Do your own research and due diligence before investing in any company. SOHA merely is providing information and is in no way or manner suggesting an investment in any company or investment opportunity. You are the investor and are making decisions for yourself. report/release/video profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.